Sign in

You're signed outSign in or to get full access.

LI

Longeveron Inc. (LGVN)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 was anchored by a full-year update: revenue rose to $2.392M (+237% y/y) on Bahamas registry demand and new contract manufacturing, with gross profit of $1.884M (+752% y/y); full-year net loss narrowed to $15.973M (-25% y/y) .
  • HLHS ELPIS II trial passed 90% enrollment and is now expected to complete in Q2 2025; FDA confirmed ELPIS II is pivotal and, if positive, acceptable for a full-approval BLA submission in 2026, positioning a clear regulatory path but with a timeline extension versus prior targets .
  • Alzheimer’s program advanced with RMAT and Fast Track designations and a late-Q1 2025 FDA meeting to discuss a potentially accelerated path; WHO approved the INN “laromestrocel” for Lomecel‑B™, strengthening commercialization readiness .
  • Cash and equivalents ended the year at $19.2M; management reiterated funding runway into Q4 2025 but flagged increased 2025 spend for CMC/manufacturing BLA-readiness and intent to pursue additional financing and non-dilutive funding .
  • Key near-term catalysts: completion of ELPIS II enrollment, FDA AD meeting outcomes, and continued CMC execution; estimate comparisons were unavailable from S&P Global due to data access limits (see Estimates Context) .

What Went Well and What Went Wrong

What Went Well

  • Revenue inflection and margin expansion: 2024 revenue reached $2.392M (+237% y/y) with gross profit of $1.884M (+752% y/y) driven by Bahamas registry and contract manufacturing; net loss improved to $15.973M (-25% y/y) .
  • HLHS regulatory clarity: FDA indicated ELPIS II is pivotal and acceptable for a full approval BLA if successful; enrollment surpassing 90% supports momentum toward a 2026 BLA timeline .
  • Alzheimer’s momentum and naming: RMAT and Fast Track designations for mild AD and WHO approval of the INN “laromestrocel” indicate regulatory traction and brand readiness; management emphasized an “accelerated path” proposal to the FDA .
    • “We are proposing a very accelerated path to the commercialization and regulatory approval… part of the RMAT [designation] gives you an opportunity for an accelerated path” — CEO Wa’el Hashad .

What Went Wrong

  • HLHS enrollment timing slipped: prior guidance targeted YE 2024/Q1 2025, but completion is now expected in Q2 2025 due to rare-disease surgery scheduling and intraoperative eligibility issues; management is pursuing composite endpoints with the FDA to ensure clinical meaningfulness .
  • Cash burn to increase: 2025 operating and capital expenditures will accelerate for CMC/manufacturing readiness ahead of BLA; management intends to pursue financing and non-dilutive sources, introducing funding execution risk .
  • Limited quarterly disclosure: Q4 was reported as full-year with limited quarterly granularity (EPS, segment breakdown), constraining direct quarter-on-quarter EPS comparisons for Q4 and estimate benchmarking .

Financial Results

MetricQ2 2024Q3 2024Q4 2024 (derived)
Revenue ($USD Thousands)$468 $773 $603 (FY $2,392 − 9M $1,789)
Gross Profit ($USD Thousands)$344 $682 $530 (FY $1,884 − 9M $1,354)
Gross Profit Margin %73.5% (344/468) 88.2% (682/773) 87.9% (530/603)
Total Operating Expenses ($USD Thousands)$3,844 $5,331 $4,811 (FY $18,406 − 9M $13,595)
Net Loss ($USD Thousands)$(3,413) $(4,419) $(4,081) (FY $(15,973) − 9M $(11,892))
EPS (Basic & Diluted, $)$(1.83) $(0.34) n/a (not disclosed quarterly)

Segment/Revenue Breakdown

Revenue CategoryQ2 2024Q3 2024FY 2024
Clinical Trial Revenue ($USD Thousands)$287 $210 $1,402
Contract Manufacturing Revenue ($USD Thousands)$181 $563 $487
Contract Manufacturing Lease Revenue ($USD Thousands)n/an/a$503
Total Revenue ($USD Thousands)$468 $773 $2,392

Key KPIs

KPIQ2 2024Q3 2024Q4 2024
Cash & Equivalents ($USD Millions)$12.375 $22.778 $19.232
ELPIS II Enrollment Status70% (27/38) >80% >90%; 35 patients enrolled
ELPIS II Enrollment Completion GuidanceYE 2024 target YE 2024/Q1 2025 Q2 2025
HLHS BLA Timing (if successful)Type C feedback pending; plan in 2026 context 2026 anticipated 2026 anticipated
AD FDA Meeting TimingBefore YE 2024 Q1 2025 Late Q1 2025

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
ELPIS II Enrollment CompletionHLHSYE 2024 or Q1 2025 Q2 2025 Lowered/Delayed
HLHS BLA Submission (if ELPIS II positive)20262026 anticipated 2026 anticipated Maintained
Cash RunwayFunding horizonThrough Q4 2025 Into Q4 2025 Maintained
2025 Spend (CMC/BLA-readiness)OpEx/CapExAcceleration expected Acceleration expected Maintained
Alzheimer’s FDA MeetingTimingQ1 2025 Late Q1 2025 Maintained (refined timing)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q4 2024)Trend
HLHS pivotal path & endpointsFDA Type C confirmed ELPIS II pivotal; alignment on primary/secondary endpoints; composite endpoint concept discussed FDA accepted composite endpoints; SAP in process; enrollment >90% and intent to complete; topline expected ~summer 2026 (12 months follow-up from last-in) Positive regulatory clarity; extended enrollment timeline
HLHS commercialization footprintMinimal sales infra anticipated (≤15 people; ~50 surgeons; 70% surgeries at trial centers) Reiterated minimal infrastructure; CDMO approach to commercial manufacturing Execution planning advancing
Alzheimer’s pathway/partnershipsRMAT/Fast Track; planning FDA meeting; seeking non-dilutive funding/partners Proposing accelerated path at late-Q1 2025 FDA meeting; partnership seen as strategic given 140+ AD programs Strategic focus; near-term regulatory engagement
CMC/BLA-readinessCTO appointed; building CDMO capability; contract manufacturing revenue ramp potential 2025 spend to accelerate for CMC; CDMO selected for commercial manufacturing; master plan in place Intensifying investment and execution
Contract manufacturing revenueQ2: $0.2M; 9M’24: $0.8M; potential $4–$5M annual longer-term FY’24: $1.0M (incl. $0.5M lease); ’25 outlook opportunistic given CMC commitments Growing but opportunistic near-term

Management Commentary

  • “ELPIS II has now achieved more than ninety percent enrollment and we expect to complete enrollment in the second quarter of this year… [ELPIS II] is pivotal and… acceptable for [a] BLA submission for full traditional approval.” — CEO Wa’el Hashad .
  • “We are working to prepare… convincing evidence that composite endpoint would be the way to go… including hospitalization, survival and other endpoints.” — CMO Nataliya Agafonova .
  • “WHO… approved ‘laromestrocel’ for the non-proprietary name of Lomecel‑B™. This naming approval is an important step in… potential commercialization.” — CEO Wa’el Hashad .
  • “Operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025… including CMC and manufacturing readiness… we intend to seek additional financing and non-dilutive funding options.” — CFO Lisa Locklear .

Q&A Highlights

  • HLHS enrollment delay drivers and endpoint strategy: Rare-disease surgical scheduling and intraoperative eligibility reduced predictability; FDA agreed to composite clinical endpoints (e.g., hospitalization, survival) and will review SAP; team targets completion within “one or two months” from >90% mark, now formalized to Q2 2025 .
  • Topline timeline and BLA: If last patient enrolled by Q2 2025, 12-month follow-up implies topline in summer 2026; rolling BLA submission targeted thereafter if positive .
  • Commercialization footprint: HLHS commercialization expected to require small team (≤15) targeting ~50 surgeons, with majority at trial centers, enabling efficient launch .
  • Manufacturing revenue outlook: Relationship with Secretome may produce small 2025 work; near-term focus on CMC/BLA readiness may limit CDMO capacity expansion .
  • Partnership lens for AD: An accelerated FDA-endorsed path would be a de-risking milestone to open strategic discussions amid many competing programs .

Estimates Context

  • Consensus EPS/revenue estimates from S&P Global for Q4 2024 were unavailable due to data access limits; as a result, beat/miss analysis versus Wall Street consensus could not be performed. If needed, we can re-attempt retrieval later to anchor estimate comparisons on S&P Global data [functions.GetEstimates error].

Key Takeaways for Investors

  • HLHS remains the nearest-term value driver: FDA pivotal acceptance and >90% enrollment are de-risking milestones; the timeline extension to Q2 2025 for enrollment pushes topline to summer 2026, but a clear 2026 BLA path is intact .
  • Focus on composite endpoints should strengthen clinical meaningfulness and approvability; FDA alignment reduces regulatory uncertainty .
  • Alzheimer’s RMAT/Fast Track and late-Q1 2025 FDA meeting could catalyze partnering; an accelerated path would materially change capital needs and timelines .
  • CMC/manufacturing readiness will drive 2025 spend; CDMO strategy mitigates pre-approval inspection risk but heightens near-term financing needs — monitor funding execution and dilution .
  • Revenue base broadened with contract manufacturing and Bahamas registry; FY’24 revenue growth/margin expansion reflect early platform monetization while core programs advance .
  • Trading lens: stock likely sensitive to FDA AD meeting outcomes, ELPIS II enrollment completion updates, and funding announcements; headline risk (delays vs. regulatory clarity) remains a key driver .